Literature DB >> 25599619

Clinical trials. Rituximab for maintenance of remission in AAV.

Anisha Tanna1, Charles Pusey1.   

Abstract

Maintenance therapy for antineutrophil cytoplasmic antibody-associated vasculitis (AAV) should reduce rates of relapse with minimal toxicity. The MAINRITSAN trial—the first randomized controlled trial to compare the efficacies of rituximab and azathioprine in AAV remission maintenance— has demonstrated a superior outcome using rituximab. These data have important implications for the management of AAV.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25599619     DOI： 10.1038/nrneph.2014.254

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


  10 in total

1.  Rituximab versus cyclophosphamide for ANCA-associated vasculitis.

Authors:  John H Stone; Peter A Merkel; Robert Spiera; Philip Seo; Carol A Langford; Gary S Hoffman; Cees G M Kallenberg; E William St Clair; Anthony Turkiewicz; Nadia K Tchao; Lisa Webber; Linna Ding; Lourdes P Sejismundo; Kathleen Mieras; David Weitzenkamp; David Ikle; Vicki Seyfert-Margolis; Mark Mueller; Paul Brunetta; Nancy B Allen; Fernando C Fervenza; Duvuru Geetha; Karina A Keogh; Eugene Y Kissin; Paul A Monach; Tobias Peikert; Coen Stegeman; Steven R Ytterberg; Ulrich Specks
Journal:  N Engl J Med       Date:  2010-07-15       Impact factor: 91.245

2.  Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.

Authors:  Rachel B Jones; Jan Willem Cohen Tervaert; Thomas Hauser; Raashid Luqmani; Matthew D Morgan; Chen Au Peh; Caroline O Savage; Mårten Segelmark; Vladimir Tesar; Pieter van Paassen; Dorothy Walsh; Michael Walsh; Kerstin Westman; David R W Jayne
Journal:  N Engl J Med       Date:  2010-07-15       Impact factor: 91.245

3.  Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Rona M Smith; Rachel B Jones; Mary-Jane Guerry; Simona Laurino; Fausta Catapano; Afzal Chaudhry; Kenneth G C Smith; David R W Jayne
Journal:  Arthritis Rheum       Date:  2012-11

Review 4.  B-cell-targeted therapy in adult glomerulonephritis.

Authors:  Anisha Tanna; Frederick W K Tam; Charles D Pusey
Journal:  Expert Opin Biol Ther       Date:  2013-11-05       Impact factor: 4.388

5.  Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): ten-year experience at a single center.

Authors:  Rodrigo Cartin-Ceba; Jason M Golbin; Karina A Keogh; Tobias Peikert; Marta Sánchez-Menéndez; Steven R Ytterberg; Fernando C Fervenza; Ulrich Specks
Journal:  Arthritis Rheum       Date:  2012-11

6.  Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis.

Authors:  Loïc Guillevin; Christian Pagnoux; Alexandre Karras; Chahera Khouatra; Olivier Aumaître; Pascal Cohen; François Maurier; Olivier Decaux; Jacques Ninet; Pierre Gobert; Thomas Quémeneur; Claire Blanchard-Delaunay; Pascal Godmer; Xavier Puéchal; Pierre-Louis Carron; Pierre-Yves Hatron; Nicolas Limal; Mohamed Hamidou; Maize Ducret; Eric Daugas; Thomas Papo; Bernard Bonnotte; Alfred Mahr; Philippe Ravaud; Luc Mouthon
Journal:  N Engl J Med       Date:  2014-11-06       Impact factor: 91.245

7.  Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis.

Authors:  Mark A Little; Peter Nightingale; C A Verburgh; Thomas Hauser; Kirsten De Groot; Caroline Savage; David Jayne; Lorraine Harper
Journal:  Ann Rheum Dis       Date:  2009-07-01       Impact factor: 19.103

Review 8.  Pathogenesis of antineutrophil cytoplasmic autoantibody-mediated disease.

Authors:  J Charles Jennette; Ronald J Falk
Journal:  Nat Rev Rheumatol       Date:  2014-07-08       Impact factor: 20.543

9.  Long-term maintenance therapy using rituximab-induced continuous B-cell depletion in patients with ANCA vasculitis.

Authors:  William F Pendergraft; Frank B Cortazar; Julia Wenger; Andrew P Murphy; Eugene P Rhee; Karen A Laliberte; John L Niles
Journal:  Clin J Am Soc Nephrol       Date:  2014-03-13       Impact factor: 8.237

10.  2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides.

Authors:  J C Jennette; R J Falk; P A Bacon; N Basu; M C Cid; F Ferrario; L F Flores-Suarez; W L Gross; L Guillevin; E C Hagen; G S Hoffman; D R Jayne; C G M Kallenberg; P Lamprecht; C A Langford; R A Luqmani; A D Mahr; E L Matteson; P A Merkel; S Ozen; C D Pusey; N Rasmussen; A J Rees; D G I Scott; U Specks; J H Stone; K Takahashi; R A Watts
Journal:  Arthritis Rheum       Date:  2013-01
  10 in total
  5 in total

1.  Effect of Continuous B Cell Depletion With Rituximab on Pathogenic Autoantibodies and Total IgG Levels in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.

Authors:  Frank B Cortazar; William F Pendergraft; Julia Wenger; Charles T Owens; Karen Laliberte; John L Niles
Journal:  Arthritis Rheumatol       Date:  2017-03-31       Impact factor: 10.995

Review 2.  Place in therapy of rituximab in the treatment of granulomatosis with polyangiitis and microscopic polyangiitis.

Authors:  Shivani Shah; Duvuru Geetha
Journal:  Immunotargets Ther       Date:  2015-08-07

Review 3.  Central Nervous System Involvement in ANCA-Associated Vasculitis: What Neurologists Need to Know.

Authors:  Yang Zheng; Yinxi Zhang; Mengting Cai; Nanxi Lai; Zhong Chen; Meiping Ding
Journal:  Front Neurol       Date:  2019-01-10       Impact factor: 4.003

4.  Rituximab use in adult glomerulopathies and its rationale.

Authors:  Joana Eugénio Santos; David Fiel; Ricardo Santos; Rita Vicente; Rute Aguiar; Iolanda Santos; Manuel Amoedo; Carlos Pires
Journal:  J Bras Nefrol       Date:  2019-12-20

5.  Danger-associated molecular pattern molecules and the receptor for advanced glycation end products enhance ANCA-induced responses.

Authors:  Theresa H Page; Derick Chiappo; Francesca Brunini; Josep Garnica; Jack Blackburn; Fayaz Dudhiya; Maria Prendecki; Stephen P McAdoo; Charles D Pusey
Journal:  Rheumatology (Oxford)       Date:  2022-02-02       Impact factor: 7.580
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.